Please assess the completion status of the following clinical trial:

Trial Title: TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed HER2 positive invasive breast carcinoma~* Clinical stage Ⅱ-ⅢC~* Eastern Cooperative Oncology Group(ECOG) performance status 0 to 1 within 14 days of study entry~* Normal (greater than 50%) left ventricular ejection fraction (LVEF) by echocardiography~* Signed informed consent~* Adequate organ function within 2 weeks of study entry:~Absolute neutrophil count \>1500/mm3, Hgb \>9.0 g/dl and platelet count \>100,000/mm3 Total bilirubin \< upper limit of normal Creatinine \< 1.5 mg/dL or calculated cranial cruciate ligament (CrCL) \>50mL/min using the Cockcroft Gault equation serum glutamate oxaloacetate transaminase(SGOT)(AST) or serum glutamic oxaloacetic transaminase(SGPT)(ALT) and Alkaline Phosphatase must be within the range allowing for eligibility~* Patients must be over 18 years old.~* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment~* Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation.~Exclusion Criteria:~* Metastatic disease~* Prior chemotherapy, hormonal therapy, biologic therapy, investigational agent, targeted therapy or radiation therapy for current breast cancer. Patients with history of breast cancer greater than 5 years from initial diagnosis are eligible for the study. Patients may not have received anthracycline-based chemotherapy in the past. Patients with history of ductal carcinoma in situ(DCIS) are eligible if there were treated with surgery alone.~* History of previous or current malignancy at other sites with the exception of adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma of the skin. Patients with a history of other malignancies, who remain disease free for greater than five years are eligible.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TCH (Type: EXPERIMENTAL): docetaxel/carboplatin/trastuzumab
- EC-TH (Type: ACTIVE_COMPARATOR): epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).